Table 2.

Cross-linking in pediatric keratoconus: summary of the studies' characteristics and overall results.

Study	Type	N   patients/eyes	Age (yrs.)	M/F ratio	Amsler-Krumeich classification	F-up before CXL (mo.)	CXL Technique	F-up after CXL (mo.)	Safety	Efficacy
Caporossi et al. [30]	P	152/77	10–18	4/1	≤III	12–36	Standard	36	+	+
Caporossi et al. [31]	P	10/10	11–18				Transepithelial	24	+	−
Vinciguerra et al. [32]	P	40/40	9–18	31/9	II	3	Standard	24	+	+
Buzzonetti and Petrocelli [42]	P	13/13	8–18	12/1	≤III		Transepithelial	18	+	−
Zotta et al. [33]	R	4/8	11–15	1/3		6–9	Standard	36	+	+
Chatzis and Hafezi [34]	R	42/59	9–19	29/13	I–IV		Standard	36	+	−
Arora et al. [40]	P	15/15	10–15		I-II		Standard	12	+	+
Bakshi et al. [35]	R	9/9	11–17	1/0		12	Standard	24	+	+
Magli et al. [36]	R	19/23 11/16	12–17 12–17	14/5 8/3		6 6	Standard Transepithelial	12	+	+
Shetty et al. [37]	P	18/30	11–14				Accelerated 9 mW/cm2 for 10 minutes	24	+	+
Ozgurhan et al. [39]	R	38/44	9–18	14/5			Accelerated 30 mW/cm2 for 4 minutes	24	+	+
Salman [41]	P	22/22	13–18	9/2		12	Transepithelial	12	+	+
Soeters et al. [38]	P	—/31	12–17				Standard	12	+	+
Kodavoor et al. [43]	R	24/35	9–16				Standard	12	+	+
Viswanathan et al. [45]	P	18/25	8–17	13/5	I–III		Standard	6–48	+	+
Sabti et al. [46]	C	1/2	4	1/0		3	Standard	36	+	+

F-up: follow-up, CXL: cross-linking, P: prospective, R: retrospective, C: case report, (+): favorable outcome, and (−): unfavorable outcome.